Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.38 |
| ▸ | CDK1 | P06493 | 3/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | ADA | P00813 | 4/20 | 0.35 |
| ▸ | PDE2A | O00408 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15214191 | 0.94 | ADORA2A (0.43) | ADORA2AADORA2BADORA1CCNB2CDK1 | |
| SCHEMBL12112278 | 0.83 | TSHR (0.39) | ADORA2AADORA2BADORA1CCNB2CDK1 | |
| SCHEMBL21539425 | 0.72 | ADORA2A (0.78) | ADORA2AADORA2BADORA1PI4KAPI4K2B | |
| SCHEMBL23774610 | 0.72 | ADORA2A (0.52) | ADORA2AADORA2BADORA1CCNB2CDK1 | |
| SCHEMBL22381514 | 0.70 | CYP1A2 (0.55) | ADORA2AADORA2BADORA1CCNB2CDK1 | |
| SCHEMBL23619296 | 0.67 | HPRT1 (0.46) | ADORA2AADORA2BADORA1SLC29A1LMNA | |
| SCHEMBL12112259 | 0.65 | ADORA2A (0.54) | ADORA2AADORA2BADORA1PI4KAPI4K2B | |
| SCHEMBL22381495 | 0.64 | ADORA2A (0.74) | ADORA2AADORA2BADORA1PI4KAPI4K2B | |
| SCHEMBL24026378 | 0.64 | SLC29A1 (0.45) | ADORA2AADORA2BADORA1CDK1CCNB1 | |
| SCHEMBL12113559 | 0.64 | ADORA2A (0.52) | ADORA2AADORA2BADORA1CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160319366-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160319366-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-03 | — | — | US | disclosed |
| US-9322831-B2 | DDX3 as a biomarker for cancer and methods related thereto | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-04-26 | — | — | US | disclosed |
| US-9322831-B2 | DDX3 as a biomarker for cancer and methods related thereto | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-04-26 | — | — | US | disclosed |
| WO-2014149084-A2 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20130281440-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY | 2013-10-24 | — | — | US | disclosed |
| US-20130281440-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY | 2013-10-24 | — | — | US | disclosed |
| US-8518901-B2 | Fused diimidazodiazepine compounds and methods of use and manufacture thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518901-B2 | Fused diimidazodiazepine compounds and methods of use and manufacture thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110275588-A1 | Fused Diimidazodiazepine Compounds and Methods of Use and Manufacture Thereof | HOSMANE, RAMACHANDRA S. | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160319366-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | DDX3X, DDB1, DDX24 | ADORA2A 4578/4885ADORA2B 4349/4885ADORA1 4375/4885 |
| US-20110275588-A1 | Fused Diimidazodiazepine Compounds and Methods of Use and Manufacture Thereof | IKZF3, AADAC, IKBKE | ADORA2A 2862/4885ADORA2B 2714/4885ADORA1 3039/4885 |
| US-20130281440-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | DDX3X, DDB1, DDX24 | ADORA2A 4578/4885ADORA2B 4349/4885ADORA1 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.